CHARACTERIZATION OF THE HEMODYNAMIC-RESPONSE TO INTRAVENOUS DIASPIRIN CROSS-LINKED HEMOGLOBIN SOLUTION IN RATS

被引:52
|
作者
MALCOLM, DS
HAMILTON, IN
SCHULTZ, SC
COLE, F
BURHOP, K
机构
[1] WASHINGTON HOSP CTR,DEPT SURG,WASHINGTON,DC 20010
[2] WASHINGTON HOSP CTR,DEPT TRAUMA CRIT CARE,WASHINGTON,DC 20010
[3] BAXTER HLTHCARE CORP,BLOOD SUBSTITUTES PROGRAM,ROUND LAKE,IL
关键词
D O I
10.3109/10731199409117402
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Diaspirin crosslinked hemoglobin solution (DCLHb(TM)) has potential for clinical use as an oxygen-carrying solution because of its excellent oxygen transport properties and biochemical stability. The present study characterizes the effects of intravenous infusions of 0.625-40 mL/kg (62.5-4000 mg/kg) DCLHb on mean blood pressure (MAP) and heart rate (HR) in conscious rats. DCLHb at all doses tested except 62.5 mg/kg was associated with an immediate increase in MAP (25-30% above baseline) that peaked between 20-30 minutes after infusion and returned to baseline within 120-300 minutes in a dose-dependent manner. Maximum MAP achieved was in the range of 129 +/- 7 to 140 +/- 7 mm Hg and there was no statistically significant difference in the response between doses. HR responded in a reciprocal manner to changes in MAP. Volume- and oncotic-matched infusions of LR and albumin did not alter MAP or HR. Slow infusion (0.34 mL/min) of DCLHb appeared to blunt the magnitude of the presser response when compared to bolus injection (<10 sec). DCLHb administration is associated with a presser response that is not due to volume load, oncotic pressure, or rate of infusion, suggesting that it is intrinsic to the modified hemoglobin molecule and pharmacologic in nature.
引用
收藏
页码:91 / 107
页数:17
相关论文
共 50 条
  • [21] Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution
    Przybelski, RJ
    Daily, EK
    Kisicki, JC
    MattiaGoldberg, C
    Bounds, MJ
    Colburn, WA
    CRITICAL CARE MEDICINE, 1996, 24 (12) : 1993 - 2000
  • [22] Modulation of resuscitative effect of diaspirin cross-linked hemoglobin by L-NAME in rats
    Sen, AP
    Dong, YM
    Saxena, PR
    Gulati, A
    SHOCK, 1998, 9 (03): : 223 - 230
  • [23] The effects of diaspirin cross-linked hemoglobin on hemodynamics, metabolic acidosis, and survival in burned rats
    Soltero, RG
    Hansbrough, JF
    JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1999, 46 (02): : 286 - 291
  • [24] Evaluation of the immunogenicity of diaspirin cross-linked hemoglobin (DCLHb(TM)).
    Webb, EJ
    Shelbourn, TE
    Moore, EG
    MattiaGoldberg, C
    Patel, MJ
    FASEB JOURNAL, 1996, 10 (06): : 341 - 341
  • [25] Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients
    Swan, SK
    Halstenson, CE
    Collins, AJ
    Colburn, WA
    Blue, J
    Przybelski, RJ
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 26 (06) : 918 - 923
  • [26] IMMUNOGENICITY OF DIASPIRIN CROSS-LINKED HUMAN HEMOGLOBIN-SOLUTIONS
    ESTEP, TN
    GONDER, J
    BORNSTEIN, I
    AONO, F
    BIOMATERIALS ARTIFICIAL CELLS AND IMMOBILIZATION BIOTECHNOLOGY, 1992, 20 (2-4): : 603 - 609
  • [27] The effect of diaspirin cross-linked hemoglobin on coagulation in surgical patients
    OHara, JF
    Tetzlaff, JE
    Udayashankar, SV
    Connors, DF
    Bedocs, NM
    Schubert, A
    ANESTHESIOLOGY, 1997, 87 (03) : A230 - A230
  • [28] DIASPIRIN CROSS-LINKED HEMOGLOBIN (DCLHB(TM)) DOES NOT AFFECT THE ANESTHETIC POTENCY OF ISOFLURANE IN RATS
    COLE, DJ
    PRZYBELSKI, RJ
    SCHELL, RM
    MARTIN, RD
    ARTIFICIAL CELLS BLOOD SUBSTITUTES AND IMMOBILIZATION BIOTECHNOLOGY, 1995, 23 (01): : 89 - 99
  • [29] Actions of diaspirin cross-linked hemoglobin on isolated rat and dog vessels
    Hart, JL
    Ledvina, MA
    Muldoon, SM
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 129 (03): : 356 - 363
  • [30] The effects of diaspirin cross-linked hemoglobin on the tone of human saphenous vein
    Forrest, MR
    Chester, AH
    Royston, D
    ANESTHESIA AND ANALGESIA, 2001, 92 (02): : 324 - 328